◈ Nootpedia
Compact view
Research pass: redirect Compound OTHER HIGH

Elvanse (redirect)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OTHER HIGH

"Elvanse" is the EU/UK trade name for the same molecule sold in the US/CA/AU as Vyvanse — both are lisdexamfetamine dimesylate manufactured by Takeda (originally Shire). Pharmacology, dosing, evidence, scheduling rationale, and Dylan verdict (SKIP-FOR-NOW MEDIUM, with conditional flip to STRONG-CANDIDATE on formal ADHD or BED diagnosis) are identical. This file exists as a name-search stub for users who know the compound by the EU brand.

Research pass: redirect
▸ Sourcing deep dive

For Dylan or anyone reading from a UK/EU vantage:

  • UK NHS: Elvanse available on NHS prescription for diagnosed ADHD; specialist titration usually starts at adult psychiatry. Prescription cost capped at NHS rate (~£10/month).
  • UK private: Private psychiatry route via Harley Street / online providers (Psychiatry-UK, ADHD 360) — diagnostic eval £400-1500, then private Rx ~£60-150/month.
  • EU private: Country-specific; Germany requires BtM (narcotic) prescription, France similar. All routes require formal diagnosis.
  • Cross-border import: Schedule II equivalent in most EU jurisdictions; no legitimate gray-market path.

The sourcing decision tree for Dylan's case (US-based, no diagnosis) is fully covered in vyvanse.md and unchanged by EU branding — he'd be shopping in the US Vyvanse market regardless.

▸ Cross-references

For full mechanism (RBC aminopeptidase activation of the L-lysine prodrug → d-amphetamine release → DAT/NET reuptake inhibition + TAAR1-mediated efflux + VMAT2 displacement), evidence (A-tier ADHD efficacy adults+children, A-tier BED efficacy as only FDA-approved BED pharmacotherapy, B-tier brain-development concerns at age 20 per Reynolds 2023 + 2025), dosing protocols, side effects + risks (cardiovascular, sleep, appetite, dependence), tolerance + cycling, stacking, drug interactions (MAOI hard contraindication, urinary pH effects), pharmacogenomics (COMT, CYP2D6, DAT1), sourcing, decision matrix, biomarkers, controversies, and Dylan-archetype verdict (SKIP-FOR-NOW MEDIUM — same brain-dev concern as Adderall + 12-14 hr duration colliding with Dylan's late chronotype migration, conditional flip to STRONG-CANDIDATE on formal ADHD/BED diagnosis):

  • vyvanse.md — canonical entry, thorough research pass
▸ Sources (full, with our context)
Back to compact view